After Year-Long Review, Varmus Removes “Reasonable Pricing” Clause From CRADA
In Brief: Comis Named ECOG Chairman; Long Joins Capitol Associates; Chabner Day In Shelbyville
Advisors’ Report On Intramural Program To Recommend Restructuring
Russian-American Breast Cancer Meeting Canceled
Breast Cancer Plan Issues Its First RFA, Other Initiatives To Be Announced Soon
NCI, EORTC Offer Support For Russian Cancer Researchers
Public Forum On NRSA Tuition Policies
Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- Peter F. Garrett to people with cancer: Your story has power
- What NHS-Galleri taught us—and what it didn’t
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”









